Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

SAN DIEGO, Aug. 25 /PRNewswire/ -- NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

DAS181 (Fludase((R))) is an investigational drug candidate in clinical development for Influenza-Like Illness. Unlike neuraminidase inhibitors (e.g. Tamiflu((R))), which target the virus, DAS181 works by inactivating the human host receptor for all influenza and para-influenza viruses tested so far including the current pandemic Novel H1N1 strain ("Swine Flu"). Previous preclinical studies conducted in collaboration with the Centers for Disease Control and Prevention have shown DAS181 to have significant prophylactic and therapeutic activity in an in vivo animal model for a highly virulent H5N1 (A/VN/1203/04) strain of influenza. The current published study, conducted in collaboration with the University of Hong Kong, examined for the first time the effects of DAS181 in human lung tissue and cells. DAS181 strongly inhibited H5N1 (A/VN/3046/2004) infection in human lung tissue and cells. The study also demonstrated that DAS181 effectively removes the two types of sialic acid (Sia) receptors to which influenza virus binds, thereby preventing both the invasion by virus into new cells and further replication where infection already exists.

The human lung tissue and cells described have been critical models for understanding the clinical pathogenesis of influenza, as people contain two types of receptors for influenza. While H5N1 preferentially binds to A2-3-linked Sia, Novel H1N1 preferentially binds to A2-6-linked Sia. DAS181 was shown in these studies to remove both the A2-6-linked and A2-3-linked types found in human respiratory tissue. Most importantly, virus was suppressed by inactivation of the entry receptors by DAS181 treatment.
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... - EastMed Inc., the medical manufacturing company that caters ... clearance to market its flagship product, uresta(TM) Continence Care, ... to get the official word from the FDA," said ... (TM) Continence Care offers an innovative and cost-effective option ...
... Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced ... the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... the American Society of Hematology (ASH) in San Francisco, ... presentation is entitled "Phase I/II Trial of the XIAP ...
... a business unit of DSM Pharmaceutical Products, and Dutch,biotechnology company ... today announced that Hungary-based Gedeon Richter Plc. signed a,commercial license ... the PER.C6(R) platform. , ... About PER.C6(R) technology , ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:4/14/2014)... David Kisailus, the Winston Chung Endowed Chair ... Riverside,s Bourns College of Engineering, has been named ... scientists selected by the advisory board of the ... Sciences and organizers of the Kavli/National Academy of ... Foundation, which is based in Oxnard, supports scientific ...
(Date:4/14/2014)... you feel when an elevator zips you up multiple floors ... elevator carried you all the way up to the top ... , That,s similar to what many fish experience when they ... the change in pressure is simply too big, too fast, ... article in the March issue of the journal Fisheries ...
(Date:4/14/2014)... Chicago,s Field Museum and international collaborators have reconstructed the ... the New World tropics, the region of the Earth ... nuclear DNA sequences uncovered three species new to science, ... Since 1960, when modern studies on this group began, ... 22. The newest additions were described in a ...
Breaking Biology News(10 mins):Professor receives young scientist honor 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3
... to new research funded by the Economic and Social ... Open University, led by Professor Andy Lane, has taken ... not those mainly involved in organic growing - ... and the food industry regard GM, but this is ...
... is the ultimate destination for anyone interested in natural history ... broadly about our responsibilities to all life on Earth. Thats ... and the Environment at The University of Nottingham, who has ... Observer for the International Association of Antarctica Tour Operators (IAATO). ...
... Now think of bacteria eating rock below the ocean ... 15,000 feet underwater" With a $3.9 million grant ... Katrina Edwards will lead a first-of-its-kind drilling expedition to ... which live on chemical reactions with rock and water, ...
Cached Biology News:What farmers think about GM crops 2Observing sustainable tourism in Antarctica 2Observing sustainable tourism in Antarctica 3USC awarded $3.9M for lab under the sea 2
In plasmid or lambda vector. Please inquire for more details!...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Biology Products: